Does Insurance Cover Ketamine Treatment?

Does insurance cover ketamine treatment? The answer depends entirely on which form of ketamine is involved and how it's administered. FDA-approved esketamine (Spravato), a nasal spray for treatment-resistant depression, is covered by most commercial insurance plans and Medicare Part D, usually after prior authorization. Off-label intravenous (IV) racemic ketamine, prescribed for depression, PTSD, or chronic pain, is generally not covered by insurance because the FDA has not approved this route and formulation for psychiatric indications. Compounded ketamine products, such as sublingual troches or nasal sprays used for at-home therapy, are also typically excluded from insurance formularies since they are not FDA-approved products. Knowing which category applies to your treatment is the first step in understanding what you'll actually pay out of pocket.

Spravato (Esketamine) Insurance Coverage

Commercial Insurance

Most major commercial insurance carriers cover Spravato for its FDA-approved indications: treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal ideation. Spravato is the brand name for esketamine, a nasal spray that the FDA approved in 2019 for use alongside an oral antidepressant. That approval status is what makes routine insurance coverage possible, since most plans base psychiatric drug coverage on FDA-approved indications.

Coverage is typically subject to prior authorization, meaning the prescribing physician must document that the patient meets specific clinical criteria before the insurer will pay.

Approval is not automatic, and initial requests may be denied. Appeals processes exist and can be successful, particularly when supported by detailed clinical documentation and peer-reviewed evidence.

Medicare

Medicare Part D covers Spravato for its approved indications, following standard Part D benefit structures. Patients are responsible for applicable deductibles, copayments, and coinsurance, and out-of-pocket costs vary by plan and by which benefit phase the patient is in (deductible, initial coverage, coverage gap, or catastrophic). Medicare Advantage (Part C) plans may also cover Spravato, but coverage terms vary, so patients should verify details with their specific plan.

Medicaid

Medicaid coverage for Spravato varies by state. Some state Medicaid programs cover it with prior authorization, while others apply more restrictive policies or exclude it entirely. Patients enrolled in Medicaid should contact their state Medicaid office or managed care plan for current coverage information.

Facility and Monitoring Fees

An important detail that's easy to overlook: insurance coverage for Spravato may apply only to the medication itself, not the facility and monitoring fees tied to the required two-hour observation period after each dose. Some clinics bill the observation and monitoring separately, and coverage for those charges varies by plan. Ask in advance whether both the medication and the facility fees are covered under your policy.

IV Racemic Ketamine Coverage

The Off-Label Challenge

IV racemic ketamine for psychiatric indications is prescribed off-label, meaning it's used for conditions not listed on the FDA-approved label. Off-label prescribing is legal and common in medicine, but most insurance companies do not cover off-label IV ketamine infusions for depression, PTSD, or other psychiatric conditions. See our comparison of racemic ketamine and esketamine for how the two forms differ clinically.

Reasons insurers typically decline coverage include:

• Absence of FDA approval for the specific psychiatric indication
• Classification of the treatment as experimental or investigational
• Lack of treatment protocols that meet the insurer's evidence thresholds
• Concerns about the cost-effectiveness of ongoing maintenance infusions

Exceptions and Special Cases

In limited circumstances, insurance may cover aspects of IV ketamine treatment:

• Workers' compensation: some workers' compensation plans have covered ketamine infusions for chronic pain claims
• Military and VA healthcare: the Department of Veterans Affairs has explored ketamine therapy for veterans with treatment-resistant conditions, and coverage may be available through VA medical centers
• Out-of-network benefits: some patients have obtained partial reimbursement by submitting claims under out-of-network mental health benefits
• State legislative changes: the insurance landscape is evolving, and some states have considered legislation that would require coverage for off-label ketamine therapy

Superbills and Reimbursement

Some ketamine clinics provide superbills, which are detailed receipts patients can submit to their insurance company for potential reimbursement. Full reimbursement is unlikely, but patients with out-of-network mental health benefits may recover a portion of the cost. Success depends on the specific plan terms, the diagnostic codes used, and the insurer's policies. Ask a prospective clinic whether they issue superbills before you commit; our guide on how to find a ketamine provider covers other questions worth asking during that search.

Compounded Ketamine Coverage

Compounded ketamine formulations, including sublingual troches, nasal sprays, and topical preparations, are generally not covered by insurance. These are not FDA-approved products, and most insurance formularies exclude compounded medications outright. Patients typically pay out of pocket for both the compounding pharmacy fees and the prescriber's consultation fees.

Some patients have reported success getting reimbursed for the prescriber consultation portion of at-home ketamine therapy, particularly when the visit is billed as a psychiatric evaluation or medication management appointment with appropriate diagnostic and procedure codes. This depends heavily on how the clinic codes the visit and the specifics of the patient's plan.

Strategies for Navigating Insurance

Maximizing Spravato Coverage

Patients pursuing Spravato coverage can improve their odds of approval with a few practical steps.

Exploring Alternative Coverage Pathways

Federal and state mental health parity laws add another avenue for appeal. The Mental Health Parity and Addiction Equity Act (MHPAEA) is a federal law requiring that insurance coverage for mental health and substance use conditions be comparable to coverage for physical health conditions. If an insurer covers comparable medical treatments but denies coverage for ketamine-based psychiatric treatment, a parity argument may support an appeal.

Most states also offer an external review process, where an independent reviewer evaluates an insurance denial after internal appeals are exhausted. Filing a complaint with the state insurance department can sometimes prompt an insurer to reconsider a denial as well.

The Future of Coverage

The insurance landscape for ketamine therapy continues to shift. Several trends point toward broader coverage over time, including growing clinical evidence supporting ketamine's efficacy, increasing mainstream acceptance of ketamine therapy in psychiatric practice, potential future FDA approvals for additional ketamine-based products, state-level legislative efforts to mandate or expand coverage, and employer interest in covering effective depression treatments given the cost of lost productivity and disability claims. For more on where esketamine treatment stands heading into next year, see our esketamine treatment-resistant depression outlook for 2026.

Significant barriers remain, particularly for off-label IV ketamine and compounded formulations, until additional FDA approvals are granted or insurance policies change. Many patients will continue to bear substantial out-of-pocket costs for these forms of treatment in the meantime. For a full breakdown of typical costs across treatment types, see how much ketamine treatment costs.

References

• MedlinePlus: Esketamine Nasal Spray, National Library of Medicine information on Spravato, the FDA-approved esketamine product most commonly covered by insurance
• FDA: Drug Approvals and Databases, an FDA resource on drug approval status, which directly affects insurance coverage eligibility
• StatPearls: Ketamine, a clinical reference covering ketamine's FDA-approved and off-label uses relevant to insurance coverage
• NIMH: Depression, a National Institute of Mental Health overview of depression treatment, including access and coverage considerations